Literature DB >> 23917362

Congenital adrenal hyperplasia and pregnancy.

Soulmaz Shorakae1, Helena Teede.   

Abstract

A 32-year-old woman with classical congenital adrenal hyperplasia (CAH) secondary to 21-hydroxylase deficiency presented with infertility. She was treated with different steroid replacement regimens together with fludrocortisone. The aim of this case report is to discuss fertility barriers in women with classical CAH, and emphasise the risks and benefits of available steroid treatment options. Clinical considerations covered include preconception health and fertility planning, optimising fertility through suppression of excess hormone production, reducing fetal androgen exposure in utero and limiting maternal and fetal side effects of therapy and limiting chances of CAH in the baby. In this case suppression of androgen and progesterone levels was challenging but eventually was achieved and resulted in a spontaneous pregnancy. However, she miscarried in the first trimester, and fetal biopsy revealed a complete hydatiform mole. She is advised not to conceive while she is under investigation to determine the extent of the disease.

Entities:  

Mesh:

Year:  2013        PMID: 23917362      PMCID: PMC3761662          DOI: 10.1136/bcr-2013-010299

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia.

Authors:  Anne Bachelot; Zeina Chakhtoura; Geneviève Plu-Bureau; Mathieu Coudert; Christiane Coussieu; Yasmina Badachi; Jérome Dulon; Beny Charbit; Philippe Touraine
Journal:  Eur J Endocrinol       Date:  2012-08-14       Impact factor: 6.664

2.  Mothers with congenital adrenal hyperplasia and their children: outcome of pregnancy, birth and childhood.

Authors:  N Krone; I Wachter; M Stefanidou; A A Roscher; H P Schwarz
Journal:  Clin Endocrinol (Oxf)       Date:  2001-10       Impact factor: 3.478

3.  Gestational trophoblastic disease in the Asian population of Northern England and North Wales.

Authors:  B W L Tham; J E Everard; J A Tidy; D Drew; B W Hancock
Journal:  BJOG       Date:  2003-06       Impact factor: 6.531

4.  Monitoring of menstrual cycles, ovulation, and adrenal suppression by saliva sampling in female patients with 21-hydroxylase deficiency.

Authors:  Nike M M L Stikkelbroeck; C G J Sweep; Didi D M Braat; Ad R M M Hermus; Barto J Otten
Journal:  Fertil Steril       Date:  2003-10       Impact factor: 7.329

5.  Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia.

Authors:  F Gastaud; C Bouvattier; L Duranteau; R Brauner; E Thibaud; F Kutten; P Bougnères
Journal:  J Clin Endocrinol Metab       Date:  2007-02-06       Impact factor: 5.958

6.  Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  K Hagenfeldt; P O Janson; G Holmdahl; H Falhammar; H Filipsson; L Frisén; M Thorén; A Nordenskjöld
Journal:  Hum Reprod       Date:  2008-04-16       Impact factor: 6.918

7.  Outcome of bilateral adrenalectomy in congenital adrenal hyperplasia: one unit's experience.

Authors:  Cara Megan Ogilvie; Gill Rumsby; Tom Kurzawinski; Gerard S Conway
Journal:  Eur J Endocrinol       Date:  2006-03       Impact factor: 6.664

Review 8.  Epidemiology and aetiology of gestational trophoblastic diseases.

Authors:  Andrea Altieri; Silvia Franceschi; Jacques Ferlay; Jennifer Smith; Carlo La Vecchia
Journal:  Lancet Oncol       Date:  2003-11       Impact factor: 41.316

9.  Fertility rates in female patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  R M Mulaikal; C J Migeon; J A Rock
Journal:  N Engl J Med       Date:  1987-01-22       Impact factor: 91.245

10.  Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate.

Authors:  Anna Casteràs; Purnami De Silva; Gillian Rumsby; Gerard S Conway
Journal:  Clin Endocrinol (Oxf)       Date:  2009-02-25       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.